Alain Combes

Alain Combes

Auto-generated profile, based on publicly available information

Alain Combes

Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
ACAlain Combes
Alain Combes
DHDavid Hajage
David Hajage
GCGilles Capellier
Gilles Capellier
ADAlexandre Demoule
Alexandre Demoule
SLSylvain Lavoué
Sylvain Lavoué
AMAlain Mercat
Alain Mercat
The efficacy of venovenous extracorporeal membrane oxygenation (ECMO) in patients with severe acute respiratory distress syndrome (ARDS) remains controversial.

1 March 2016 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
GMGrégoire Muller
Grégoire Muller
EFErwan Flecher
Erwan Flecher
GLGuillaume Lebreton
Guillaume Lebreton
CLCharles-Edouard Luyt
Charles-Edouard Luyt
JTJean-Louis Trouillet
Jean-Louis Trouillet
ACAlain Combes
Alain Combes

1 November 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MSMatthieu Schmidt
Matthieu Schmidt
DHDavid Hajage
David Hajage
GLGuillaume Lebreton
Guillaume Lebreton
AMAntoine Monsel
Antoine Monsel
GVGuillaume Voiriot
Guillaume Voiriot
EMElise Morawiec
Elise Morawiec

6 October 2020 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
ACAlain Combes
Alain Combes
GPGiles J. Peek
Giles J. Peek
DHDavid Hajage
David Hajage
PHPollyanna Hardy
Pollyanna Hardy
DADarryl Abrams
Darryl Abrams
DEDiana Elbourne
Diana Elbourne

1 July 2020 in The Lancet
Verified
Journal Article
Closed access
ACAlain Combes
Alain Combes
SPSusanna Price
Susanna Price
ASArthur S Slutsky
Arthur S Slutsky
DBDaniel Brodie
Daniel Brodie

28 March 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
FCFillipo Corsi
Fillipo Corsi
GLGuillaume Lebreton
Guillaume Lebreton
NBNicolas Bréchot
Nicolas Bréchot
GHGuillaume Hekimian
Guillaume Hekimian
ANAnia Nieszkowska
Ania Nieszkowska
MSMatthieu Schmidt
Matthieu Schmidt
Despite quick implementation of reperfusion therapies, a few patients with high-risk, acute, massive, pulmonary embolism (PE) remain highly hemodynamically unstable. Others have absolute contraindication to receive reperfusion therapies. Venoarterial-extracorporeal membrane oxygenation (VA-ECMO) might lower their right ventricular overload, improve hemodynamic status, and restore tissue oxygenation. ECMO-related complications and 90-day mortality were analyzed for 17 highly unstable, ECMO-treated, massive PE patients admitted to a tertiary-care center (2006–2015). Hospital- discharge survivors were assessed for long-term health-related quality of life. A systematic review of this topic was also conducted. Seventeen high-risk PE patients [median age 51 (range 18–70) years, Simplified Acute Physiology Score II (SAPS II) 78 (45–95)] were placed on VA-ECMO for 4 (1–12) days. Among 15 (82%) patients with pre-ECMO cardiac arrest, seven (41%) were cannulated during cardiopulmonary resuscitation, and eight (47%) underwent pre-ECMO thrombolysis. Pre-ECMO median blood pressure, pH, and blood lactate were, respectively: 42 (0–106) mmHg, 6.99 (6.54–7.37) and 13 (4–19) mmol/L. Ninety-day survival was 47%. Fifteen (88%) patients suffered in-ICU severe hemorrhages with no impact on survival. Like other ECMO-treated patients, ours reported limitations of all physical domains but preserved mental health 19 (4–69) months post-ICU discharge. VA-ECMO could be a lifesaving rescue therapy for patients with high-risk, acute, massive PE when thrombolytic therapy fails or the patient is too sick to benefit from surgical thrombectomy. Because heparin-induced clot dissolution and spontaneous fibrinolysis allows ECMO weaning within several days, future studies should investigate whether VA-ECMO should be the sole therapy or completed by additional mechanical clot-removal therapies in this setting.